Who Exports Sertraline from India — 218 Suppliers Behind a $560.5M Market
India's sertraline export market is supplied by 218 active exporters who collectively shipped $560.5M across 5,183 shipments. CIPLA LIMITED leads with a 55.5% market share, followed by AUROBINDO PHARMA LTD and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 88.8% of total export value, reflecting a concentrated market structure.
Top Sertraline Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading sertraline exporter from India, holding a 55.5% share of the $560.5M market across 5,183 shipments from 218 exporters. The top 5 suppliers — CIPLA LIMITED, AUROBINDO PHARMA LTD, SUN PHARMACEUTICAL INDUSTRIES LIMITED, LUPIN LIMITED, APL HEALTHCARE LIMITED — collectively control 88.8% of total export value, indicating a highly concentrated market. Individual shares are: CIPLA LIMITED (55.5%), AUROBINDO PHARMA LTD (13.6%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (12.1%), LUPIN LIMITED (5.3%), APL HEALTHCARE LIMITED (2.3%).
Top Sertraline Exporters from India
Ranked by export value · 218 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED SERTRALINE TABLETS, USP 25 MG NDC 69097-833-12 ANDA 077397 | $311.1M | 2 | 55.5% |
| 2 | AUROBINDO PHARMA LTD SERTRALINE HYDROCHLORIDE TABLETS 50MG(SESERTRALINE 100MG TABLETS(SERTRALIN ORIONSERTRALINE TABLETS, USP 25 MG NDC 69097-833-12 ANDA 077397 | $76.5M | 20 | 13.6% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED SERTRALINE 100MG TABLETS(SERTRALIN ORIONSERTRALINE SUN TAB 100MG PACK : BOX 2X14SERTRALINE TABLETS 100MG PACK :BOX 2X14S | $67.8M | 16 | 12.1% |
| 4 | LUPIN LIMITED SERTRALINE TABLETS, USP 25 MG NDC 69097-833-12 ANDA 077397PHARMA : SERTRALINE TABLETS 50MG KYOWA JAPAN - 1'SPHARMA : SERTRALINE TABLETS 25MG KYOWA JAPAN - 1'S | $29.5M | 6 | 5.3% |
| 5 | APL HEALTHCARE LIMITED SERTRALINE TABLETS, USP 25 MG NDC 69097-833-12 ANDA 077397 | $13.0M | 1 | 2.3% |
| 6 | TORRENT PHARMACEUTICALS LTD SERTRALINE HCL TAB 50MG PACK:BOX100X10SOTHER - SERENATA 50 TABLET ( SERTRALINESERTRALINE HCL TAB 50MG PACK:BOX50X10S B | $10.7M | 8 | 1.9% |
| 7 | GRANULES INDIA LIMITED SERTRALINE TABLETS, USP 25 MG NDC 69097-833-12 ANDA 077397 | $9.6M | 1 | 1.7% |
| 8 | IPCA LABORATORIES LIMITED NOUMED SERTRALINE 50MG TABLETS 30'S PRODHARMLESS MEDICINES:APO-SERTRALINE 100MG R.HARMLESS MEDICINES:APO-SERTRALINE 100MG( | $7.4M | 10 | 1.3% |
| 9 | AUROBINDO PHARMA LIMITED SERTRALINE HYDROCHLORIDE TABLETS 50MG(SESERTRALINE 100MG TABLETS(SERTRALIN ORIONSERTRALINE TABLETS, USP 25 MG NDC 69097-833-12 ANDA 077397 | $6.6M | 16 | 1.2% |
| 10 | EMCURE PHARMACEUTICALS LIMITED SERTRALINE TABLETS, USP 25 MG NDC 69097-833-12 ANDA 077397SERTRALINE 100MG CAPSULES(AURO-SERTRALINSERTRALINE CAPSULES 25MG(AURO-SERTRALINE | $3.5M | 2 | 0.6% |
| 11 | TORRENT PHARMACEUTICALS LIMITED SERTRALINE HCL TAB 50MG PACK:BOX100X10SOTHER - SERENATA 50 TABLET ( SERTRALINESERTRALINE HCL TAB 50MG PACK:BOX50X10S B | $2.7M | 5 | 0.5% |
| 12 | MEDREICH LIMITED SERTRALINE HYDROCHLORIDE TABLETS 100MG 28SSERTRALINE HYDROCHLORIDE TABLETS 50MG 28'SSERTRALINE HYDROCHLORIDE TABLETS 100MG(S | $2.4M | 1 | 0.4% |
| 13 | INTAS PHARMACEUTICALS LIMITED SERTRALINE HYDROCHLORIDE TABLETS 50MG(SESERTRALINE TABLETS, USP 25 MG NDC 69097-833-12 ANDA 077397SERTRALINE HYDROCHLORIDE TABLETS 100MG(S | $2.3M | 12 | 0.4% |
| 14 | ZYDUS LIFESCIENCES LIMITED SERTRALINE HCL TAB 50MG PACK:BOX100X10SSERTRALINE HCL TAB 50MG PACK:BOX50X10S BSERTRALINE 50MG TABLETS 30'S | $2.0M | 9 | 0.4% |
| 15 | EMIL PHARMACEUTICAL INDUSTRIES PVT LTD | $1.8M | 3 | 0.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Sertraline exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Aurobindo Pharma Limited | Approved | Yes, multiple produc | Yes | 41 (Jan–Sept 2023) | FDA warning letter issued in June 2019 for GMP deviations at Pydibhimavaram faci |
| Lupin Limited | Approved | Yes, multiple produc | Yes | 15 (Jan–Sept 2023) | FDA warning letters addressed; committed to zero warning letters by FY25. |
| Emcure Pharmaceuticals Limited | Approved | Yes, multiple produc | Yes | Not verified | FDA warning letter issued for Hinjawadi facility; under remediation. |
| Zydus Lifesciences Limited | Approved | Yes, multiple produc | Yes | 59 (Jan–Sept 2023) | 16 out of 33 facilities inspected by FDA; compliance maintained. |
| Sun Pharmaceutical Industries Limited | Approved | Yes, multiple produc | Yes | 10 (Jan–Sept 2023) | Consistent FDA approvals; ongoing compliance with regulatory standards. |
| Cipla Limited | Approved | Yes, multiple produc | Yes | Not verified | Maintains compliance with FDA and WHO standards; no recent warning letters. |
| Dr. Reddy's Laboratories Limited | Approved | Yes, multiple produc | Yes | Not verified | All facilities fully compliant with FDA regulations as of March 31, 2024. |
| Torrent Pharmaceuticals Limited | Approved | Yes, multiple produc | Yes | Not verified | Maintains compliance with FDA and WHO standards; no recent warning letters. |
TransData Nexus reviewed the regulatory standing of 8 leading Sertraline exporters from India. 8 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Sertraline sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy's Laboratories and Aurobindo Pharma. This concentration of expertise and infrastructure makes Hyderabad a critical center for API manufacturing, including Sertraline.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses major companies like Zydus Cadila and Torrent Pharmaceuticals. The region's robust infrastructure and regulatory compliance make it a key player in the production of finished pharmaceutical products, including Sertraline tablets.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a significant export gateway for pharmaceuticals. Mumbai, being India's financial capital, provides access to major ports and international markets. The region hosts numerous pharmaceutical companies with a strong focus on export-oriented manufacturing, facilitating the global distribution of drugs like Sertraline.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub. The region offers tax incentives and houses over 1,000 pharmaceutical manufacturing units, including major players like Cipla and Torrent Pharmaceuticals. This makes Baddi a strategic location for cost-effective production of pharmaceuticals, including Sertraline.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 88.8% of Sertraline exports, consider engaging with a broader range of suppliers to mitigate risks associated with supplier concentration.
- Evaluate API and Formulation Capabilities: Assess suppliers based on their capabilities in both API production and formulation to ensure a comprehensive supply chain for Sertraline.
- Leverage Export Hubs: Utilize regions like Mumbai-Thane-Raigad for efficient export logistics, taking advantage of established infrastructure and proximity to international markets.
- Consider Cost Advantages: Explore manufacturing units in tax incentive zones like Baddi-Nalagarh to benefit from cost efficiencies in production.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can optimize its supply chain for Sertraline, ensuring reliability, cost-effectiveness, and compliance with international standards.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Sertraline exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires remaining stake in Taro Pharmaceuticals
Sun Pharma entered into a definitive merger agreement to acquire the remaining stake in Taro Pharmaceuticals for $347.73 million. - IMPACT: This acquisition is expected to enhance Sun Pharma's product portfolio, potentially increasing its Sertraline export capabilities.
Impact: This acquisition is expected to enhance Sun Pharma's product portfolio, potentially increasing its Sertraline export capabilities.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
Sun Pharma acquired Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology treatments, for $355 million. - IMPACT: While primarily focused on oncology, this acquisition may bolster Sun Pharma's overall manufacturing and R&D capabilities, indirectly benefiting Sertraline production.
Impact: While primarily focused on oncology, this acquisition may bolster Sun Pharma's overall manufacturing and R&D capabilities, indirectly benefiting Sertraline production.
Lupin Limited — Lupin acquires French pharmaceutical company Medisol
Lupin entered into an agreement to acquire Medisol, a French pharmaceutical company, expanding its presence in the European market. - IMPACT: This acquisition is likely to enhance Lupin's distribution network in Europe, potentially increasing Sertraline exports to the region.
Impact: This acquisition is likely to enhance Lupin's distribution network in Europe, potentially increasing Sertraline exports to the region.
Common Questions — Sertraline Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which sertraline supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 550 recorded shipments worth $311.1M. AUROBINDO PHARMA LTD (683 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (642 shipments) are also established high-volume exporters.
Q How many sertraline manufacturers are there in India?
India has 218 active sertraline exporters with a combined export market of $560.5M across 5,183 shipments to 88 countries. The top 5 suppliers hold 88.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for sertraline from India?
Average FOB unit price: $2.15 per unit, ranging from $0.00 to $600.00. Average shipment value: $108.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 218 verified Indian exporters of Sertraline ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 5,183 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 88 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
5,183 Verified Shipments
218 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists